Clinical Trials
21
Active:0
Completed:6
Trial Phases
4 Phases
Phase 2:12
Phase 3:3
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 2
12 (66.7%)Phase 3
3 (16.7%)Phase 4
2 (11.1%)Not Applicable
1 (5.6%)Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Recruiting
- Conditions
- Small-cell Lung CancerRadiationResidual Tumor
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06514118
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China
Nutrition Impact on Immunotherapy of Cancer
Phase 3
Recruiting
- Conditions
- Nutrition DisordersCancerSurvival, ProsthesisImmunotherapy
- Interventions
- Drug: Megestrol Acetate and olanzapineDrug: Starch powder 50 mg
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06500234
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06138028
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
🇨🇳Qingdao Central Hospital, Qingdao, Shandong, China
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05392257
- Locations
- 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China
Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
Phase 2
Recruiting
- Conditions
- PFSOS
- Interventions
- Drug: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 117
- Registration Number
- NCT05267366
- Locations
- 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found